UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported)
[October 17, 2005]
BioSpecifics
Technologies Corp
(Exact
name of registrant as specified in its charter)
|
Delaware |
0-19879 |
11-3054851 |
|
(State
or Other Jurisdiction |
(Commission
File Number) |
(I.R.S.
Employer |
|
Of
Incorporation) |
|
Identification
No.) |
| |
|
|
35
Wilbur Street, Lynbrook, NY 11563
(Address
of Principal Executive Office) (Zip Code)
516.593.7000
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
Name or Former Address, If Changed Since Last Report.)
Item
8.01. Other events
On
October 17, 2005, the Board of Directors of BioSpecifics Technologies Corp.
accepted the resignation of Edwin H. Wegman as its President. Mr. Wegman remains
with the Company as its Chairman and Chief Executive Officer. The Board of
Directors elected Thomas L. Wegman to the position of President.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant
has duly caused this report to be signed on its behalf by the
undersigned
hereunto duly authorized.
BioSpecifics
Technologies Corp.
By: /s/
Lawrence Dobroff
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Lawrence
Dobroff
Chief
Financial Officer
Dated:
October 19, 2005
INDEX
TO EXHIBITS
|
Exhibit No. |
|
Exhibit
Title |
| |
|
|
| |
|
|